ReviewMolecular imaging and biology2012
Dual-labeling strategies for nuclear and fluorescence molecular imaging: a review and analysis.
Review in Molecular imaging and biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Bimodal nanobody agents for cancer imaging and potential intraoperative guidance: a systematic review.Journal of nanobiotechnology · 2026Pooled it
- Surgical radioguidance with beta-emitting radionuclides; challenges and possibilities: A position paper by the EANM.European journal of nuclear medicine and molecular imaging · 2024Guideline
- Multimodality PET and Near-Infrared Fluorescence Intraoperative Imaging of CEA-Positive Colorectal Cancer.Molecular imaging and biology · 2023Article
- The Blood-Brain Barrier: Implications for Experimental Cancer Therapeutics.Annual review of cancer biology · 2023Article
- High-resolution and high-speed 3D tracking of microrobots using a fluorescent light field microscope.Quantitative imaging in medicine and surgery · 2023Article
- Biodistribution of Multimodal Gold Nanoclusters Designed for Photoluminescence-SPECT/CT Imaging and Diagnostic.Nanomaterials (Basel, Switzerland) · 2022Article
- Synthesis and characterization of fluorescence poly(amidoamine) dendrimer-based pigments.Scientific reports · 2022Article
- Dual-Labelling Strategies for Nuclear and Fluorescence Molecular Imaging: Current Status and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Targeted Dual-Modal PET/SPECT-NIR Imaging: From Building Blocks and Construction Strategies to Applications.Cancers · 2022Review
- Pharmacokinetics and Excretion Study ofFoods (Basel, Switzerland) · 2021Article
- Modular Synthesis of Peptide-Based Single- and Multimodal Targeted Molecular Imaging Agents.ACS applied bio materials · 2021Article
- Comparison of HER2-Targeted Antibodies for Fluorescence-Guided Surgery in Breast Cancer.Molecular imaging · 2021Article
- Hybrid Imaging Agents for Pretargeting Applications Based on Fusarinine C-Proof of Concept.Molecules (Basel, Switzerland) · 2020Article
- Study on Absorption Mechanism and Tissue Distribution of Fucoidan.Molecules (Basel, Switzerland) · 2020Article
- Modular Synthesis of DOTA-Metal-Based PSMA-Targeted Imaging Agents for MRI and PET of Prostate Cancer.Chemistry (Weinheim an der Bergstrasse, Germany) · 2019Article
- A Dual-Modality Linker Enables Site-Specific Conjugation of Antibody Fragments forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Near-Infrared-II Molecular Dyes for Cancer Imaging and Surgery.Advanced materials (Deerfield Beach, Fla.) · 2019Review
- New Developments in Dual-Labeled Molecular Imaging Agents.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Review
- Recent progress on micro- and nano-robots: towardsQuantitative imaging in medicine and surgery · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Molecular imaging is used for the detection of biochemical processes through the development of target-specific contrast agents. Separately, modalities such as nuclear and near-infrared fluorescence (NIRF) imaging have been shown to non-invasively monitor disease. More recently, merging of these modalities has shown promise owing to their comparable detection sensitivity and benefited from the development of dual-labeled imaging agents. Dual-labeled agents hold promise for whole-body and intraoperative imaging and could bridge the gap between surgical planning and image-guided resection with a single, molecularly targeted agent. In this review, we summarized the literature for dual-labeled antibodies and peptides that have been developed and have highlighted key considerations for incorporating NIRF dyes into nuclear labeling strategies. We also summarized our findings on several commercially available NIRF dyes and offer perspectives for developing a toolkit to select the optimal NIRF dye and radiometal combination for multimodality imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.